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ValidationAbstract Purpose: The objective of the current study is to evaluate the Ultra Performance Liquid
Chromatography (UPLC) method for quantiﬁcation of Acyclovir in lipid-based formulations.
Method: A simple, rapid, reliable and precise reversed phase UPLC method has been developed
and validated according to the regulatory guidelines, which composed of isocratic mobile phase;
0.25% formic acid (FA) in Milli-Q water with a ﬂow rate of 0.5 ml/min, and column BEH C18
(2.1 · 50 mm, 1.7 lm). The detection was carried out at 254 nm.
Results: The developed UPLC method was found to be rapid (1.2 min run time), selective with
well resoluted Acyclovir peak (0.89 min) from different lipid matrices and sensitive (Limit of Detec-
tion (LOD) was 0.3 ppm and Lower Limit of Quantiﬁcation (LLOQ) was 1 ppm). The accuracy and
precision were determined and were perfectly matching with the standard FDA limits.
Conclusion: The study showed that the proposed UPLC method can be used for the assessment
of drug purity, stability, solubility and lipid-formulation release proﬁle with no interference of
excipients or related substances of active pharmaceutical ingredient.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Acyclovir (ACV) is chemically known as 2-amino-1,9-dihydro-
9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one (Fig. 1). Acyclo-
vir is the most commonly used oral antiviral agent for the
treatment and prophylaxis of initial and recurrent episodes
of genital and labial herpes and also for the acute treatment
of herpes zoster and the varicella (chickenpox) in immunocom-
petent individuals. As an antiviral therapy it is extremely selec-
tive and low in cytotoxicity. According to the
pharmacokinetics data ACV is poorly water soluble and it
has low, variable and incomplete absorption which leads toid-based
Figure 1 Chemical structure of Acyclovir (MW: 225.21, pKa:
2.27 and 9.25).
2 K.A. Al-Amri et al.poor bioavailability ranging from 10 to 30%. Maximum
plasma concentration is reached within 1.5–2.5 h, when ACV
is administered orally (Arnal et al., 2008).
ACV was previously analyzed with several analytical meth-
ods like High Performance Liquid Chromatography (HPLC)
(Teshima et al., 2003, Basavaiah et al., 2003), micellar liquid
chromatography (Peh and Yuen, 1997; Macka et al., 1993),
gas chromatography (Leis et al., 2002, Rakestraw, 1993), capil-
lary electrophoresis (Vo et al., 2002, Reichova et al., 2002),
radioimmunoassay (Tadepalli and Quinn, 1996), and potenti-
ometry (Abdel-Ghani et al., 2002). None of these methods were
specially developed in lipid based formulations except biological
ﬂuids and few inAcyclovir dosage forms (suspension). There are
many drawbacks with the previously mentioned analytical
methods such as lengthy and tedious process, lack of required
sensitivity or may have required synthetic/special reagents or
detectors. Thus, an improved analytical method for ACV
should be developed demandingmore sensitivity, speed and also
required to meet the stability-indicating parameter.
In the current project, the assay method for ACV was devel-
oped and validated using a relatively new Ultra Performance
Liquid Chromatography (UPLC) system that carries many
advantages over HPLC or any other conventional analysis
methodwhich reduces analysis time and solvent use signiﬁcantly.
The solvent used as the mobile phase was only water mixed with
0.25% formic acid. Within the experimental method develop-
ment, it was also needed to carry out stability studies under
forced acidic, alkaline, thermal, and oxidative degradation pro-
cesses. The special feature of UPLC device allows for the system
towithstand highback pressurewithout any harmful effect to the
analytical column or the whole device (Abdel-Hamid et al., 2012,
Nova´kova´ et al., 2006). This proposed method was also success-
fully applied to the analysis of lipid-based formulations contain-
ing ACV with no interference from dosage form excipients. The
method was validated with respect to the standard FDA guide-
lines (US Dept. of Health and Human Services, 2001).
2. Materials
ACV (purity >99.5) was generously donated by Riyadh
Pharma Medical and Cosmetic Products Co. LTD, Riyadh
11451, Saudi Arabia. Imwitor 308 (I308) was kindly supplied
by Sasol Germany GmbH (Werk Witten, Witten-Germany).
Propylene glycol (PG) and Tween 80 (T80) were obtained from
Winlab, BDH and Merck-Schuchardt. The mobile phase was
HPLC-grade 0.25% formic acid which was prepared by adding
5 ml of formic acid (obtained from BDH laboratory, BDH
Chemicals Ltd., Poole, UK with purity of 98–100%) to two
liters of Milli-Q water. The high purity Milli-Q water was
obtained through a Milli-Q Integral Water Puriﬁcation System
(Millipore, Bedford, MA). All other reagents were of analyti-
cal grade and used without further puriﬁcation.Please cite this article in press as: Al-Amri, K.A. et al., Development and validation o
formulations. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arab3. Methods
3.1. UPLC chromatographic conditions
Chromatographic separation was developed and optimized
with respect to the stationary and mobile phase compositions,
ﬂow-rate, sample volume, and detection wavelength. The study
employed a highly sensitive UPLC system that consisted of an
Acquity UPLC binary solvent manager equipped with an
Acquity automatic sample manager and a Photodiode Array
(PDA) ek detector obtained from Waters (Waters Inc.,
Bedford, MA, USA). Separation was achieved by reverse-
phase isocratic elution using a mobile phase consisting of
0.25% formic acid (0.25% FA) in Milli-Q water delivered at
a ﬂow rate of 0.5 ml/min through an Acquity UPLC BEH
C18 column (2.1 · 50 mm, 1.7 lm) kept at 50 C. The run time
was 1.2 min. Freshly prepared mobile phase was ﬁltered
through an online 0.20 lm ﬁlter and degassed continuously
by an online degasser within the UPLC system. The detector
wavelength was set at 254 nm and the injection volume was
1.0 ll.
3.2. Preparation of stock solution, calibration standards and QC
samples
Stock solution of ACV was prepared by dissolving 50 mg ACV
powder in 50 ml distilled water, resulting in a solution contain-
ing 1000 ppm ACV. Serial standard dilutions (9 points) of
ACV were prepared to cover the concentration range of 1–
400 ppm. These standard solutions were stored at 4 C before
use. Calibration curves were obtained by plotting peak area
against standard drug concentration and regression equations
were computed thereby. Four quality control (QC) samples
with the selected concentrations (1.48, 64.48, 287.76, and
377.12 ppm) were prepared to cover the desired range. QC
samples were prepared by spiking the lipid-formulation with
known amount of ACV, then diluting the mixture with appro-
priate volume of water containing 0.25% FA.
3.3. Formulation matrix effect
Direct spectrophotometric analysis of the drug compound may
experience spectral overlapping between the analyte and excip-
ients used in the dosage form, which signiﬁcantly affects the
sensitivity, accuracy and precision of the method (Yu et al.,
2008). Therefore it was required to perform UPLC spectral
scanning for both drug-containing and drug-free formulations
to detect any possible interference. In this study, the analyte
(ACV) was loaded in lipid based formulation from low to
high concentrations in order to test the extent of the matrix
effect..
3.4. Bioanalytical method validation
The above mentioned developed method was validated in
terms of linearity, speciﬁcity, precision and accuracy, Limit
of Detection (LOD) and Lower Limit of Quantiﬁcation
(LLOQ) according to the standard guidelines of bioanalytical
method validation (US Dept. of Health and Human
Services, 2001; Gao et al., 2011) by FDA.f a UPLC method for quantiﬁcation of antiviral agent, Acyclovir in lipid-based
jc.2014.08.024
Quantiﬁcation of acyclovir in lipid based formulations 33.4.1. Linearity and range
Appropriate volumes of ACV stock solution (1000 ppm) were
utilized to prepare nine non-zero standard drug concentrations
covering the calibration range of 1–400 ppm. Four different
QC samples were prepared by spiking known concentrations
of ACV within the detection range of 1–400 ppm.
Each standard solution (1, 2, 5, 10, 20, 50, 100, 200 and
400 ppm) has been injected six consecutive times daily on three
consecutive days for validation. Calibration solutions were
injected in ascending order in each validation run and the
other samples were distributed randomly through the run.
Linear regression equation and correlation coefﬁcient (R2)
were employed to statistically evaluate the linearity of the
results (Ali et al., 2006; Lister, 2005; Al-Hadiya et al., 2010).
3.4.2. Speciﬁcity
Speciﬁcity of the method needed to be assessed for the evalu-
ation of the matrix effect between the drug and different
lipid-based formulations (details in matrix effect section).
To evaluate the speciﬁcity of the method, drug free
lipid formulation (QCzero) samples were carried out through
the assay procedure and the retention times of the lipid formu-Figure 2 UPLC chromatograms of blank sample (A), standard so
formulation (QCzero) sample (C), and drug-containing lipid formulatio
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(Al-Hadiya et al., 2010). In addition, speciﬁcity of the method
toward the intact drug was also studied by determination of
the resolution (R) between the drug peak and the nearest deg-
radation product if present (Dongre et al., 2008).
3.4.3. Accuracy and precision
Intra-day accuracy and precision evaluations were performed
using six replicate determinations of nine ACV standards
within the same day. Inter-day accuracy and precision were
assessed by six replicate analyses of the following: LLOQ,
low, medium and high QC samples on three consecutive days.
The overall precision of the method was expressed as relative
standard deviation and accuracy of the method was expressed
in terms of % drug recovered (Gao et al., 2011).
3.4.4. Limit of Detection (LOD) and Lower Limit of
Quantiﬁcation (LLOQ)
The LOD and LLOQ were determined by serial dilutions of
ACV stock solutions in order to obtain signal to noise (S/N)
ratio of at least 3:1 for LOD and 10:1 for LLOQ (Lister,
2005).lution of ACV at concentration of 400 ppm (B), drug-free lipid
n (QC2) sample (D).
f a UPLC method for quantiﬁcation of antiviral agent, Acyclovir in lipid-based
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4 K.A. Al-Amri et al.4. Results and discussion
4.1. Chromatographic separation
Fig. 2 shows the representative chromatograms of blank sam-
ple (A), standard solution of ACV (B), drug-free lipid formu-
lation (QCzero) sample (C), drug-containing lipid formulation
(QC2) sample (D).
Separation and detection of ACV without any interference
were ideal by the developed UPLC assay. The chromato-
graphic result of UPLC technique in the current study shows
that the sensitivity and selectivity of this procedure are good
enough to determine ACV within the available excipients.
The ACV analyte was well separated at a retention time ofFigure 3 Typical UPLC chromatograms of: (A) acid hydrolysis-de
degraded ACV, and (D) thermal-degraded ACV.
Please cite this article in press as: Al-Amri, K.A. et al., Development and validation o
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(Fig. 2A–D). The total run time was 1.2 min, where the peaks
were of good shape and completely resolved.
4.2. Matrix effect
The assessments of matrix effect represented an integral part of
validation for quantitative analysis of drug in lipid based for-
mulations within this analytical method development. The
matrix effects at four concentration levels of ACV were
assessed. In the present analysis, the overall process efﬁciency
demonstrated that the proposed method was practically free
from relative matrix effects for the determination of ACV in
lipid based formulation.graded ACV, (B) base hydrolysis-degraded ACV, (C) oxidative-
f a UPLC method for quantiﬁcation of antiviral agent, Acyclovir in lipid-based
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The force degradation experiment in the studies was conducted
by treating model drug ACV with 1 N HCl, 1 N NaOH, 3%
H2O2 under 100 C temperature for 2 h at water bath. In case
of thermal degradation the experiment was carried out under
120 C temperature in an oven. All the ACV sample solutions
used in forced degradation studies were prepared with ﬁnal
concentrations of 400 lg/ml (400 ppm). The results of the deg-
radation study showed that the concentrations of ACV in the
samples were lowered compared to the original concentrations.
This degradation study was particularly important for the
analysis of lipid based formulation, which was not performed
previously (Basavaiah et al., 2003, Macka et al., 1993).
4.3.1. Acid degradation
This study has been made to show the degradation products of
ACV using the acid degradation method. ACV stock solution
of 400 ppm was prepared; 10 ml of it was transferred to a
100 ml volumetric ﬂask and then10 ml of 1 M hydrochloric
acid solution was added. The solutions in the ﬂask were mixed
well and kept for 2 h at 100 C temperature. After cooling the
solution at room temperature, 10 ml of 1 M sodium hydroxide
solution was added to a 100 ml volumetric ﬂask to neutralize
and then diluted to 100 ml with the mobile phase, 0.25% FA
in water. The chromatogram of the acid degradation is shown
in Fig. 3A.
4.3.2. Basic degradation
10 ml of the stock solution (400 ppm) was transferred into a
100 ml volumetric ﬂask and treated with 10 ml of 1 M sodium
hydroxide solution. The contents of the ﬂask were mixed well
and kept for 2 h at 100 C temperature. After cooling the solu-
tion at room temperature, 10 ml of 1 M hydrochloric acid
solution was added to a 100 ml volumetric ﬂask to neutralize
and then diluted to 100 ml with the mobile phase, 0.25% FA
in water. The result of the basic degradation is shown in
Fig. 3B.Figure 4 UPLC calibration curve of ACV in
Please cite this article in press as: Al-Amri, K.A. et al., Development and validation o
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10 ml of the stock solution (400 ppm) was transferred to a
100 ml volumetric ﬂask and treated with 10 ml of 3% hydro-
gen peroxide H2O2 and then heated in water bath at 100 C
for 2 h. The sample was cooled to room temperature and then
the volume completed to 100 ml with the mobile phase 0.25%
FA in water. The sample was injected in the UPLC system.
The chromatogram of the oxidation data is shown in Fig. 3C.
4.3.4. Thermal degradation
Thermal degradation experiment was conducted at elevated
temperature. 10 ml of the stock solution (400 ppm) was trans-
ferred to a 100 ml volumetric ﬂask, and kept in oven at 120 C
for 24 h. After cooling the solution at room temperature, the
0.25% FA in water was added up to 100 ml as diluent. The
chromatogram of the thermal degradation study is shown in
Fig. 3D.
4.4. System suitability
The performance parameters of the developed UPLC system
method were determined by analyzing standard working solu-
tion (400 ppm). Analytical parameters such as capacity factor
(k) and number of theoretical plates (N) were calculated
against the availability of ACV peak only. In addition, system
repeatability was determined by calculating the relative stan-
dard deviation (% RSD) of the peak areas of six consecutive
injections of working standard solution (400 ppm). From the
overall analysis, the variation (% RSD) in the peak area
(0.47%), capacity factor (k= 1.66) and number of theoretical
plates (N= 5069.4) results shows the acceptable performance
of the systems (Table 3).
4.4.1. Bioanalytical method validation
4.4.1.1. Linearity and range. The peak area response of ACV
was linear over the concentration range between 1 and
400 ppm (Fig. 4). The results of linear regression give the fol-
lowing mean equation:water containing 0.25% formic acid (FA).
f a UPLC method for quantiﬁcation of antiviral agent, Acyclovir in lipid-based
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Table 1 UPLC data of intra-day back-calculated ACV concentrations of the calibration standards in water containing 0.25% formic
acid.
Nominal conc. (ppm) Back calculated concentrations (ppm)
1st 2nd 3rd 4th 5th 6th Mean SD Precision % Accuracy %
1 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0 0 90
2 2.1 2.1 2 2 2.1 2 2.05 0.055 2.67 102.50
5 5.3 5.4 5.3 5.2 5.4 5.3 5.32 0.052 0.97 106.33
10 10.6 10.4 10.2 10.4 10.4 10.5 10.42 0.160 1.54 104.17
20 20 19.6 19.5 18 18 18.1 18.87 0.845 4.49 94.33
50 49.9 46.1 49.9 49.8 49.9 50.4 49.33 1.604 3.25 98.67
100 99.8 99.8 99.3 98.4 100.3 99.5 99.52 0.383 0.38 99.52
200 200.4 200.3 202.3 201.3 202.8 202.1 201.53 1.071 0.53 100.77
400 403.6 400 399.3 399.6 398.1 399.8 400.07 1.876 0.47 100.02
Table 2 UPLC data of inter-day accuracy (recovery) and
precision of ACV QC samples.
Day of analysis QC1 QC2 QC3 QC4
1.48 ppm 64.48 ppm 287.76 ppm 377.12 ppm
1st day 1.4 66.5 289.8 377.8
1.3 66.9 289.4 377.6
1.3 66.6 291 373.1
1.3 66.6 290.2 376.1
1.3 60.8 290.4 373.8
1.3 66.7 289.4 373.9
2nd day 1.4 69.7 290.3 376.5
1.5 69.7 290.9 375.1
1.4 70.2 287.9 374.7
1.4 69.8 289.3 376.1
1.5 69.7 290.2 376.2
1.5 70.1 289.3 374.5
3rd day 1.5 71.4 292.6 376.6
1.5 71.5 290.3 376.4
1.5 71.8 290.4 376.1
1.5 71.5 293.8 375.9
1.5 71.7 290.3 378.9
1.5 71.2 292.2 375.8
Mean 1.42 69.02 290.43 375.84
SD 0.09 2.84 1.36 1.48
Precision 6.17 4.12 0.47 0.39
Accuracy 96.09 107.04 100.93 99.66
6 K.A. Al-Amri et al.y ¼ 113:906ð1:30946Þxþ 21:62037ð2:119667Þ
where y denotes the peak area of the analyte and x denotes the
concentration of the analyte. These results show excellent lin-
earity over the interval studied with correlation coefﬁ-
cient(r) = 0.9993 (±0.007272) (Mulholland and Hibbert,
1997).
4.4.1.2. Accuracy recovery. The accuracy was calculated as the
% of drug recovered after analysis relative to the correspond-
ing nominal concentrations. The intra-day (Table 1) accuracy
(mean recoveries, mean ± SD) was found between 90% and
106.33% and the inter-day (Table 2) accuracy (mean recover-
ies, mean ± SD) was found between 96.09% and 107.04%.
The results from the drug recovery suggest that the accuracy
of the assay method has been well matched with the acceptance
criteria of FDA guidelines (US Dept. of Health and Human
Services, 2001).
4.4.1.3. Precision. The results of intra-day and inter-day preci-
sion are presented in Table 1 and Table 2, respectively. The
developed method was found to be precise as the intra-day
standard deviation (SD) values (Table 1) of six replicate anal-
yses were within the range of 0–1.87 ppm. In the analytical
range of 1–400 ppm (conc.), the coefﬁcient of variation (CV;
precision) was only ranging from 0% to 4.49%. Moreover,
the inter-day (Table 1) SD values of six replicate determina-
tions in three consecutive days were between 0.14 and
2.84 ppm, whereas the CV being in the range of 0.47%–
6.17%. These low values of both SD and CV during the
intra-day and inter-day analysis indicate perfectly the precision
of the current method (Karnes and March, 1993).
4.4.1.4. Speciﬁcity. The speciﬁcity of the developed UPLC
method for ACV was investigated in order to obtain an indica-
tion of the possible interferences from the degradation prod-
uct(s) if present. The result in Fig. 2D shows that there was
no degradation products present in the ACV sample. It seems
that ACV compound can be recovered completely from the
lipid formulation (Fig. 2D). Therefore, the R value in this
assay can be calculated based on the availability of ACV peak
only (20). In addition, there were no signiﬁcant interfering
peaks present in randomly selected drug free lipid formulation
(QCzero) samples at ACV retention time (Fig. 2C), which sug-
gests that ACV compound can be analyzed predominantly
from lipid based formulations.Please cite this article in press as: Al-Amri, K.A. et al., Development and validation o
formulations. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arab4.4.1.5. Limit of Detection (LOD) and Lower Limit of
Quantiﬁcation (LLOQ). The LLOQ in the assay was 1 ppm
which was estimated to be the lowest concentration in the stan-
dard curve that can be measured with acceptable accuracy and
precision for the ACV analyte, and with S/N ratio of 72.12. On
the other hand, LOD was 0.1 ppm with S/N ratio of 14.15.
4.5. Application
Within the scope of the current project, the developed UPLC
method has been proposed for the quantiﬁcation of ACV com-
pound in the studies of equilibrium solubility, dynamic disper-
sion and dissolution proﬁles of lipid-based formulations
(Mohsin, 2012). A dispersion proﬁle is shown in Fig. 5 as an
example of the method application. The data represented an
immediate release of ACV from a self-emulsifying lipid-based
formulation in aqueous media (Mohsin and Alanazi, 2012).f a UPLC method for quantiﬁcation of antiviral agent, Acyclovir in lipid-based
jc.2014.08.024
Table 3 Systems suitability parameters for Acyclovir (ACV),
n= 6.
System suitability parameter ACV
Standard working solution 400 ppm
Retention time 0.89 min
% RSD 0.47%
Capacity factor (k*) 1.66
Theoretical plate number (N*) 5069.4
Note: *The chromatographic conditions used were: Acquity
UPLC BEH C18 column (2.1 · 50 mm, 1.7 lm) kept at 50 C,
mobile phase was water with 0.25% formic acid (FA) delivered at a
ﬂow rate of 0.5 ml/min, a Photodiode Array (PDA) ek detector at
wavelength of 254 nm.
Figure 5 The dispersion (immediate release proﬁle) of ACV
from a self-emulsifying lipid-based formulation in aqueous
medium. Lipid formulation represents I308: PG (1:1)/T80 (1/1).
Data are expressed as mean ± SD, n= 3.
Quantiﬁcation of acyclovir in lipid based formulations 7The lipid formulation consisted mixture of medium chain
mono-glycerides (I308), water-soluble surfactant (T80) and
cosolvent (Propylene glycol) with 5 mg of ACV solubilized in
them. From the results it can be stated that the current method
quantiﬁed more than 98% ACV, which was released immedi-
ately after dispersion and stayed in solution during 24 h time
period.
5. Conclusion
The developed UPLC analytical method provides an eco-
friendly, reliable, reproducible and speciﬁc assay for ACV in
pure and pharmaceutical formulations. The described method
is sensitive enough to detect as low as 0.1 ppm and exclusively
offers a rapid determination of ACV (peak at 0.89 min within
1.2 min run time). No signiﬁcant interferences were caused by
the formulation excipients, diluents and or degradation
products.
The validation method allows quantiﬁcation of ACV in pure
and pharmaceutical formulations particularly lipid based for-
mulations in the range between 1 and 400 ppm. Compared to
previously reportedmethods, the present assaymethod assessed
extensive validation parameters as per FDA guidelines. The
method has shown acceptable precision, accuracy and adequate
sensitivity and demands to be in use for further studies.Please cite this article in press as: Al-Amri, K.A. et al., Development and validation o
formulations. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabThe established method satisﬁes the system suitability crite-
ria, peak integrity, and resolution of the drug peak. The overall
results clearly indicate that the current method is attractive due
to the good selectivity for quantitative determination of ACV
in lipid-based formulation and also suitable for stability
measurements.
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